INAB IN8BIO INC

IN8bio to Present at July Investor and Scientific Conferences

IN8bio to Present at July Investor and Scientific Conferences

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations:

  • Oppenheimer Summit for Emerging Biotechnology (Montauk), July 20
    • Patrick McCall, CFO, and Dr. Trishna Goswami, CMO, open scheduling for 1x1 partnering
  • (Boston), July 26 – 28
    • Lawrence Lamb, Ph.D., CSO, Panel for Industry Leaders’ Fireside Chat
    • July 27, 8:45 a.m. EDT



    • Lawrence Lamb, Ph.D., CSO, Presenting, “Learning from Patient Selection, Biomarker Studies, and Indications to Maximize Therapeutic Outcomes”

    • July 28, 2 p.m. EDT
  • Genetic Engineering News (GEN) Cell & Gene Therapy (CGT) Summit (Virtual), July 27
    • William Ho, CEO, Keynote on, “Challenges and Future of Allogeneic Cell Therapies”
    • July 27, 11 a.m. EDT

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit .

Contacts

IN8bio, Inc.

Patrick McCall

+1 646.600.6438

Investors:

Solebury Trout

David Buck

+1 646.378.2927

Media:

Burns McClellan, Inc.

Katie Larch / Robert Flamm, Ph.D.



EN
30/06/2022

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Trea...

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Patient with a grade 4, IDH-mutant, MGMT-methylated glioma remains alive and progression-free for four years after receiving treatment with the INB-200 gamma-delta T cell therapy in glioblastoma trial NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of INB-200 for newly-diagnosed GBM has recen...

June 9, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GB...

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival Repeated doses of INB-200 demonstrate extended median progression-free survival (mPFS) of 16.1 months, more than double the expected 6.9 months typically observed with the standard-of-care (SOC) Stupp protocolINB-200 is well-tolerated, showing no serious toxicities beyond those typically observed with chemotherapy. Importantly no cytokine release syndrome (CRS), or immune effector cell-associated neurotoxicity syndrome (ICANS) was observedMedian PFS in patients receiving...

June 2, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T C...

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell ...

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- . (...

May 12, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports First Quarter 2025 Financial Results and Recent Busines...

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings On May 1st, 2025, we celebrated the 5th anniversary of the first patient ever treated with a gamma-delta T cell therapy being developed by IN8bio. This older patient with complex AML and multiple genetic a...

May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch